Table 4.
Potential Effects on HAART drugs by Targeted Anticancer Drugs in Heat Map Format.
| Targeted Agents | Protease Inhibitors | NRTIs | NNRTIs | Other | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ritonavir | Amprenavir | Atazanavir | Indinavir | Lopinavir | Nelfinavir | Saquinavir | Tipranavir | Abacavir | Didanosine | Lamivudine | Stavudine | Zalcitabine | Zidovudine | Tenofovir | Delavirdine | Efavirenz | Nevirapine | Maraviroc | Raltegravir | |
| Imatinib | ||||||||||||||||||||
| Dasatinib | ||||||||||||||||||||
| Nilotinib | ||||||||||||||||||||
| Erlotinib | ||||||||||||||||||||
| Sunitinib | ||||||||||||||||||||
| Lapatinib | ||||||||||||||||||||
| Bortezomib | ||||||||||||||||||||
| Sorafenib | ||||||||||||||||||||
| Temsirolimus | ||||||||||||||||||||
Targeted therapies can also affect drug metabolizing enzymes by inhibiting and inducing their function. Blocks marked with red indicate a targeted therapy/HAART drug combination which may lead to higher HAART agent levels due to enzyme inhibition by the targeted agent. Blocks in green indicate a potential interaction in which patients may experience lower levels of the HAART drug due to enzyme induction by the targeted anticancer drug.